Telocytes in Umbilical Cord of Patients With and Without Pre-eclampsia

Sponsor

Sohag University (Other)

Overall Status

Recruiting

CT.gov ID

NCT05305339

Collaborator

(none)

Enrollment

Location

14.9

Anticipated Duration (Months)

2.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Studying the ultrastructural and immunohistochemical characteristics of Telocytes from umbilical cord vessels wall in PE patients compared to control and its relation to severity of disease whether controlled or uncontrolled.

Condition or Disease	Intervention/Treatment	Phase
Telocytes in Umbilical Cord of Pregnancies Complicated by Chronic Hypertension, Gestational Hypertension and Preeclampsia	Other: Placental and Umbilical cord biopsy

Detailed Description

Patients fulfilling the eligibility criteria of the current research will be approached prior to delivery. The attending physician will explain the nature of the study and all patients will be asked to sign an informed consent.

Routine investigations will be performed to all patients including CBC, liver and renal function and urine analysis in addition to albumin creatinine ratio.

Ultrasound scanning including umbilical doppler indices measurement will be done for all cases before delivery using an HDI ultrasound system (AlbiniouTL Ultrasound, Bothell, WA, USA).

Non stress test is routinely done for all hypertensive patients twice weekly as part of routine work up of such patients in our emergency unit using (CTG machine-NSL BT-350 Bistos) (Korea).

Diagnosis of chronic hypertension, gestational hypertension and preeclampsia

preeclampsia: Women with PE fulfilled the criteria if they had hypertension (> 140/90 mmHg) and proteinuria (> 0.3 gm/day or ≥ +1 by dipstick urine analysis at ≥ 20 weeks of gestation or protein-to-creatinine ratio of 0.30 or more). If no proteinuria, hypertension associated with thrombocytopenia, renal or liver impairment, or pulmonary edema was sufficient to diagnose PE as per ACOG Practice Bulletin No .202[6].
Gestational hypertension:

It is usually diagnosed when systolic blood pressure is 140 mm Hg or more or a diastolic blood pressure of 90 mm Hg or more, or both, on two occasions at least 4 hours apart after 20 weeks of gestation, in a woman with a previously normal blood pressure [7]. Gestational hypertension is considered severe when the systolic level reaches 160 mm Hg or the diastolic level reaches 110 mm Hg, or both [6].

Chronic hypertension:

It means systolic blood pressure of 140 mm Hg or more, a diastolic blood pressure of 90 mm Hg or more, or both, that is diagnosed or present before pregnancy or before 20 weeks of gestation on two occasions at least 4 hours apart. Hypertension that is diagnosed for the first-time during pregnancy and that does not resolve in the typical postpartum period also is classified as chronic hypertension[8].

Patients are finally classified to PE with severe features, PE without severe features, Gestational hypertension (mild and severe), chronic hypertension and chronic hypertension with superimposed PE and termination will be done according to the recent recommendation of ACOG [6, 8].

Tissue and samples procurement and processing:

Specimen preparation After delivery of the placenta, two tissue fragments, 1st piece about 1x1 cm from the central zone of the maternal surface of the placenta and 2nd piece about 1 x 1 cm from mid segment of umbilical cord will be cut. Each of both samples will be divided and fixed in either a 10% formalin for light microscopic examination or glutaraldehyde 2.5% for Electron microscopic examination. Paraffin-embedded placental tissue sections (4 μm thick) will be used for histological (stained with hematoxylin and eosin) and immunohistochemical examination using primary antibody markers for telocytes CD117, CD34, vimentin, SMA (smooth muscle actin), and the new telocyte marker TMEM16a (DOG-1).

Study Design

Study Type:

Observational

Anticipated Enrollment :

40 participants

Observational Model:

Cohort

Time Perspective:

Cross-Sectional

Official Title:

Telocytes in Umbilical Cord of Patients With and Without Pre-eclampsia

Actual Study Start Date :

Feb 1, 2022

Anticipated Primary Completion Date :

Feb 20, 2023

Anticipated Study Completion Date :

Apr 30, 2023

Arms and Interventions

Arm	Intervention/Treatment
Group A (Control group) Singleton pregnancies undergoing elective pre-labour CS at gestational age (34+0 to 40+0) that are otherwise healthy.	Other: Placental and Umbilical cord biopsy After delivery of the placenta, two tissue fragments, 1st piece about 1x1 cm from the central zone of the maternal surface of the placenta and 2nd piece about 1 x 1 cm from mid segment of umbilical cord will be cut. Each of both samples will be divided and fixed in either a 10% formalin for light microscopic examination or glutaraldehyde 2.5% for Electron microscopic examination. Paraffin-embedded placental tissue sections (4 μm thick) will be used for histological (stained with hematoxylin and eosin) and immunohistochemical examination using primary antibody markers for telocytes CD117, CD34, vimentin, SMA (smooth muscle actin), and the new telocyte marker TMEM16a (DOG-1).
Group B (Chronic hypertension) It means systolic blood pressure of 140 mm Hg or more, a diastolic blood pressure of 90 mm Hg or more, or both, that is diagnosed or present before pregnancy or before 20 weeks of gestation on two occasions at least 4 hours apart. Hypertension that is diagnosed for the first-time during pregnancy and that does not resolve in the typical postpartum period also is classified as chronic hypertension	Other: Placental and Umbilical cord biopsy After delivery of the placenta, two tissue fragments, 1st piece about 1x1 cm from the central zone of the maternal surface of the placenta and 2nd piece about 1 x 1 cm from mid segment of umbilical cord will be cut. Each of both samples will be divided and fixed in either a 10% formalin for light microscopic examination or glutaraldehyde 2.5% for Electron microscopic examination. Paraffin-embedded placental tissue sections (4 μm thick) will be used for histological (stained with hematoxylin and eosin) and immunohistochemical examination using primary antibody markers for telocytes CD117, CD34, vimentin, SMA (smooth muscle actin), and the new telocyte marker TMEM16a (DOG-1).
Group C (Gestational hypertension) It is usually diagnosed when systolic blood pressure is 140 mm Hg or more or a diastolic blood pressure of 90 mm Hg or more, or both, on two occasions at least 4 hours apart after 20 weeks of gestation, in a woman with a previously normal blood pressure. Gestational hypertension is considered severe when the systolic level reaches 160 mm Hg or the diastolic level reaches 110 mm Hg or both.	Other: Placental and Umbilical cord biopsy After delivery of the placenta, two tissue fragments, 1st piece about 1x1 cm from the central zone of the maternal surface of the placenta and 2nd piece about 1 x 1 cm from mid segment of umbilical cord will be cut. Each of both samples will be divided and fixed in either a 10% formalin for light microscopic examination or glutaraldehyde 2.5% for Electron microscopic examination. Paraffin-embedded placental tissue sections (4 μm thick) will be used for histological (stained with hematoxylin and eosin) and immunohistochemical examination using primary antibody markers for telocytes CD117, CD34, vimentin, SMA (smooth muscle actin), and the new telocyte marker TMEM16a (DOG-1).
Group D (Preeclampsia) Women with PE fulfilled the criteria if they had hypertension (> 140/90 mmHg) and proteinuria (> 0.3 gm/day or ≥ +1 by dipstick urine analysis at ≥ 20 weeks of gestation or protein-to-creatinine ratio of 0.30 or more). If no proteinuria, hypertension associated with thrombocytopenia, renal or liver impairment, or pulmonary edema was sufficient to diagnose PE as per ACOG Practice Bulletin No .202	Other: Placental and Umbilical cord biopsy After delivery of the placenta, two tissue fragments, 1st piece about 1x1 cm from the central zone of the maternal surface of the placenta and 2nd piece about 1 x 1 cm from mid segment of umbilical cord will be cut. Each of both samples will be divided and fixed in either a 10% formalin for light microscopic examination or glutaraldehyde 2.5% for Electron microscopic examination. Paraffin-embedded placental tissue sections (4 μm thick) will be used for histological (stained with hematoxylin and eosin) and immunohistochemical examination using primary antibody markers for telocytes CD117, CD34, vimentin, SMA (smooth muscle actin), and the new telocyte marker TMEM16a (DOG-1).

Outcome Measures

Primary Outcome Measures

Telocytes in placenta and umbilical cord [Immediately after delivery of the placenta during cesarian section of pregnancies with gestational age (34-40) weeks]
The number and distribution of Telocytes by immunohistochemistry in placenta and umbilical cord vessels wall.

Secondary Outcome Measures

Telocytes Morphology in relation to disease severity [Immediately after delivery of the placenta during cesarian section of pregnancies with gestational age (34-40) weeks]
Characterization of telocyte morphology using electron microscopy, comparing umbilical artery indices in different groups and its correlation to abundance of telocytes in examined tissues.

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A and Older

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

Study group Singleton pregnancies complicated with hypertension undergoing pre-labour CS at gestational age (34+0 to 40+0). These will be divided into 3 groups according to the type of disease either chronic hypertension (Group A), gestational hypertension (Group B) or preeclampsia (Group C).
Control group Singleton pregnancies undergoing elective pre-labour CS that are otherwise healthy.

Exclusion Criteria:

Women with history of medical co-morbidities other than hypertension were excluded from the study. This includes the following: Renal diseases, autoimmune diseases, history of organ transplantation and immunosuppressive therapy, hematological diseases, history of thrombotic events, cardiopulmonary diseases, liver diseases, Acute and chronic inflammatory diseases.
Pregnancy induced medical disorders like: Gestational thrombocytopenia.
Multiple pregnancies.
Abnormal placentation, i.e. Placenta previa and Morbidly adherent placenta.
Fetal anomalies.
vaginal deliveries and CS in labour.